AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
171.30
+1.61 (+0.95%)
At close: 4:00PM EDT

171.68 +0.38 (0.22%)
Pre-Market: 4:43AM EDT

Stock chart is not supported by your current browser
Previous Close169.69
Open169.35
Bid168.72 x 900
Ask175.05 x 800
Day's Range168.59 - 172.05
52 Week Range166.30 - 210.19
Volume2,615,458
Avg. Volume2,866,579
Market Cap104.482B
Beta (3Y Monthly)0.90
PE Ratio (TTM)13.66
EPS (TTM)12.54
Earnings DateJul 24, 2019 - Jul 29, 2019
Forward Dividend & Yield5.80 (3.23%)
Ex-Dividend Date2019-05-16
1y Target Est206.10
Trade prices are not sourced from all markets
  • Benzinga19 hours ago

    Amgen To Buy Danish Collaborator Nuevolution For $167M

    Amgen announced Wednesday an agreement to buy Copenhagen-based Nuevolution for $167 million. The U.S. company announced a recommended public cash offer to Nuevolution shareholders to tender their shares for 32.5 Swedish kronas ($3.37) each in cash. The target company's board has unanimously recommended Amgen's cash tender offer to its shareholders.

  • Reutersyesterday

    Amgen offers to buy Copenhagen-based Nuevolution for $167 mln

    Amgen, the world's largest biotechnology company, said on Wednesday it offered to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns . Amgen's cash offer of 32.5 ...

  • PR Newswireyesterday

    Amgen announces a recommended public cash offer to the shareholders of Nuevolution

    The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. Shareholders in the United States should refer to the section entitled "Important Information to U.S. Shareholders" at the end of this press release. Amgen Inc. ("Amgen") (AMGN) today announces a recommended public cash offer to the shareholders of Nuevolution AB (publ) ("Nuevolution") to tender all their shares in Nuevolution to Amgen (the "Offer").

  • PR Newswire2 days ago

    Amgen Announces Voting Results Of Annual Meeting Of Stockholders

    THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- Amgen (AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting. The director nominees Wanda M. Austin, Robert A. Bradway, Brian J. Druker, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Charles M. Holley, Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen's Board of Directors.

  • Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending
    Insider Monkey2 days ago

    Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending

    It's been a rather green day on Wall Street as all three major indexes are positive. The Dow Jones is up over 150 points while the S&P 500 is up 0.84%. Among the stocks traders are watching include Apple Inc. (NASDAQ:AAPL), Biogen Inc. (NASDAQ:BIIB), Amgen, Inc. (NASDAQ:AMGN), Deckers Outdoor Corp (NASDAQ:DECK), and Diamondback Energy Inc (NASDAQ:FANG). Let's analyze why each stock is […]

  • Benzinga3 days ago

    Medicines Company Rallies On Positive LDL Cholesterol Study Results

    Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study that is evaluating the efficacy, safety and tolerability of inclisiran 300 mg in patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol. The results show a consistent lowering of LDL cholesterol by more than 50 percent, with an overall follow-up of up to three years. The results were presented as a late-breaking presentation at the National Lipid Association Scientific Sessions in Miami.

  • Ligand Grants Preclinical Candidate Rights to UK-based Firm
    Zacks3 days ago

    Ligand Grants Preclinical Candidate Rights to UK-based Firm

    Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

  • Motley Fool6 days ago

    Who Had the Better Quarter: Gilead Sciences or Amgen?

    Here's which one of these large-cap biotechs put up the best numbers in the first quarter.

  • TheStreet.com6 days ago

    Bulls Make Money, Bears Make Money and Hogs Get Slaughtered, Jim Cramer Says

    That's Rule No. 5 of his '5 Rules for Trimming Your Winning Positions.'

  • Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
    Investor's Business Daily7 days ago

    Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting

    Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.

  • PR Newswire7 days ago

    Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference

    THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ -- Amgen (AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.

  • Here's Why Mirati Therapeutics Is Surging Today
    Motley Fool7 days ago

    Here's Why Mirati Therapeutics Is Surging Today

    Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.

  • Benzinga7 days ago

    What's Triggering The Rise In Mirati Shares?

    Mirati Therapeutics, Inc. (NASDAQ: MRTX ) shares were rallying by about 15 percent Thursday as traders circulated word that drugmaker Amgen, Inc. (NASDAQ: AMGN )  KRAS G12C  inhibitor abstract showed promising ...

  • Barrons.com7 days ago

    Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks

    The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.

  • PR Newswire7 days ago

    Amgen Showcases Oncology Pipeline At ASCO 2019

    THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancies and solid tumors. "Biology and human genetics have been the foundation of Amgen's innovation for the last four decades," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.

  • GuruFocus.com8 days ago

    Insulet and West Pharma Proven Winners in Growing Wearable Devices Market

    With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business. Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. Warning! GuruFocus has detected 4 Warning Signs with PODD.

  • 3 Stocks With Big News Coming at ASCO 2019
    Motley Fool8 days ago

    3 Stocks With Big News Coming at ASCO 2019

    These cancer drug developers could report market-moving news soon.

  • Benzinga8 days ago

    The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...

  • AbbVie Settles Humira Litigation With Boehringer Ingelheim
    Zacks8 days ago

    AbbVie Settles Humira Litigation With Boehringer Ingelheim

    AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.

  • Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
    Zacks9 days ago

    Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer

    Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.

  • The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental
    Zacks9 days ago

    The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental

    The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental

  • Introducing Amgen (NASDAQ:AMGN), A Stock That Climbed 50% In The Last Five Years
    Simply Wall St.9 days ago

    Introducing Amgen (NASDAQ:AMGN), A Stock That Climbed 50% In The Last Five Years

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Top Stock Reports for Amgen, Altria & Booking Holdings
    Zacks10 days ago

    Top Stock Reports for Amgen, Altria & Booking Holdings

    Top Stock Reports for Amgen, Altria & Booking Holdings

  • Benzinga12 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

    Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...

  • PR Newswire13 days ago

    Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference

    THOUSAND OAKS, Calif. , May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019 . David W. ...